Early indicator signs included piloerection, sustained erect ears, erect penis, clasping of hind legs when lifted by tail, rigid tail, unsustained hunched posture, mild loss of coordination, and being subdued

Early indicator signs included piloerection, sustained erect ears, erect penis, clasping of hind legs when lifted by tail, rigid tail, unsustained hunched posture, mild loss of coordination, and being subdued. benzoquinazoline-12 (BQZ-12), two highly selective positive allosteric modulators (PAMs) of M1 mAChRs. Furthermore, prolonged exposure to BQCA markedly extended the lifespan of diseased mice. Thus, enhancing hippocampal muscarinic signaling using M1 mAChR PAMs restored memory loss and slowed the progression of mouse prion disease, indicating that this ligand type may have clinical benefit in diseases showing defective cholinergic transmission, such as AD. == Introduction == Due to an aging population, it is predicted that by 2040, neurodegenerative diseases, such as Alzheimers disease (AD), will be the second most common cause of morbidity in the developed world, after cancer (1). The current frontline symptomatic treatment for AD are acetylcholinesterase (AChE) inhibitors (2). These drugs act to increase cholinergic transmission, which is reduced in AD due to a loss of cholinergic innervation to key brain regions (3, 4). Despite some clinical benefit, the nonselective mode of action of AChE inhibitors results in significant dose-related adverse effects that can limit clinical usage (2). To circumvent these adverse effects, more selective approaches to the improvement of cholinergic transmission specifically associated with memory have been pursued. In particular, activation of the M1 muscarinic acetylcholine receptor (M1 mAChR) has procognitive effects (58), making this muscarinic receptor subtype an attractive therapeutic target for AD (7). However , due to the highly conserved nature of the muscarinic receptor orthosteric ligand-binding site (9, 10), the identification of M1 mAChRselective ligands has been challenging (11). This lack of receptor subtype selectivity has resulted in the failure of numerous M1 mAChR drug discovery programs, exemplified by the mAChR ligand xanomeline a drug that relieved some of the behavioral and cognitive deficits in AD patients (12, 13), but that failed in PROTAC MDM2 Degrader-1 clinical trials due to side effects possibly due to the fact that, in addition to M1 mAChRs, xanomeline has significant action on other muscarinic receptor subtypes, including cardiac M2mAChRs and peripheral M3mAChRs (14, 15). An alternative strategy would be to target the M1 mAChR with positive allosteric modulators (PAMs) that bind to spatially distinct allosteric sites located within nonconserved receptor regions and thereby display exquisite receptor-subtype selectivity (16, 17). Although muscarinic receptor PAMs have been shown to have an impact on learning and memory (1821), these ligands have not been tested in models of progressive neurodegeneration that ultimately results in end-stage disease. Testing the action of M1 mAChR PAMs in the context of disease where cholinergic transmission is compromised, as it is in AD, is important given the fact that PAMs can act by enhancing the action of the endogenous ligand acetylcholine, thereby maintaining the spatiotemporal signaling of the endogenous ligand (17, 22), and/or by directly activating the receptor as so-called PAM agonists. Establishing which of these primary mechanisms operates to affect memory and learning PROTAC MDM2 Degrader-1 in a disease setting of end-stage neurodegeneration is fundamental to understanding the clinical potential of muscarinic receptor PAMs. The challenge lies in the fact that none of the current mouse AD models feature continued neuronal loss that ultimately results in terminal disease (23); thus, the impact and mechanism of action of muscarinic ligands in relieving symptoms of neurodegeneration or modification of disease progression in the context of progressive neurodegenerative disease have not yet been tested (24). In contrast to mouse AD models, mouse prion disease, which is characterized by an accumulation of misfolded prion protein aggregates (3, 15, 25), results in progressive neuronal loss and eventual terminal disease Tbp (24, 26, 27). Here, we show that mouse prion disease shares a number of key features with AD that include a loss of hippocampal cholinergic innervation and a cholinergic deficit that results in defective learning and memory while maintaining postsynaptic muscarinic receptors and signaling. These findings prompted us to test the activity of muscarinic ligands in prion disease, where we determined that the prion-mediated deficit in learning and memory was completely restored by the muscarinic receptor agonist xanomeline (28, 29) as well as by the highly selective M1 mAChR PAMs PROTAC MDM2 Degrader-1 benzyl quinolone carboxylic acid (BQCA) (3032) and benzoquinazoline-12 (BQZ-12) (33). Furthermore, since the mechanism of action of the M1 mAChR PAMs resulted in reduced adverse effects, we were able to test whether prolonged.